Publication: Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study
Program
Authors
YASİN, Ayşe İrem
Aydin, Sabin Goktas
SÜMBÜL, BİLGE
KORAL, LOKMAN
ŞİMŞEK, MELİH
Geredeli, Caglayan
Ozturk, Akin
Perkin, Perihan
Demirtas, Derya
Erdemoglu, Engin
Advisor
Language
Type
Publisher
Journal Title
Journal ISSN
Volume Title
Abstract
Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity.
Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive.
Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001).
Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.